Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach-Reference-Cited by-同舟云学术

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach

Published:2023-07-28 Issue:1 Volume:13 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Carobbio Alessandra^ORCID,Vannucchi Alessandro Maria,Rumi Elisa^ORCID,De Stefano Valerio^ORCID,Rambaldi Alessandro^ORCID,Carli Giuseppe,Randi Maria Luigia,Gisslinger Heinz,Passamonti Francesco^ORCID,Thiele Juergen,Gangat Naseema^ORCID,Tefferi Ayalew^ORCID,Barbui Tiziano^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-023-00887-7.pdf

Reference13 articles.

1. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–84.

2. Thiele J, Kvasnicka HM, Müllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710–8.

3. Jeryczynski G, Thiele J, Gisslinger B, Wölfler A, Schalling M, Gleiß A, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;92:885–91.

4. Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant’Antonio E, et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget. 2017;8:101735–44.

5. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-07

2. Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis;Life;2024-04-17

3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-01-25

4. Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients;Blood Cancer Journal;2024-01-23

5. Diagnosis and Management of Prefibrotic Primary Myelofibrosis (Pre-PMF);Pathogenesis and Treatment of Leukemia;2023